1. Home
  2. RIGL vs RCKT Comparison

RIGL vs RCKT Comparison

Compare RIGL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • RCKT
  • Stock Information
  • Founded
  • RIGL 1996
  • RCKT 1999
  • Country
  • RIGL United States
  • RCKT United States
  • Employees
  • RIGL N/A
  • RCKT N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • RCKT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RIGL Health Care
  • RCKT Health Care
  • Exchange
  • RIGL Nasdaq
  • RCKT Nasdaq
  • Market Cap
  • RIGL 335.5M
  • RCKT 328.6M
  • IPO Year
  • RIGL 2000
  • RCKT N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • RCKT $3.28
  • Analyst Decision
  • RIGL Buy
  • RCKT Buy
  • Analyst Count
  • RIGL 5
  • RCKT 13
  • Target Price
  • RIGL $38.20
  • RCKT $12.96
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • RCKT 6.0M
  • Earning Date
  • RIGL 08-05-2025
  • RCKT 08-07-2025
  • Dividend Yield
  • RIGL N/A
  • RCKT N/A
  • EPS Growth
  • RIGL N/A
  • RCKT N/A
  • EPS
  • RIGL 5.43
  • RCKT N/A
  • Revenue
  • RIGL $267,921,000.00
  • RCKT N/A
  • Revenue This Year
  • RIGL $59.93
  • RCKT N/A
  • Revenue Next Year
  • RIGL N/A
  • RCKT $108.43
  • P/E Ratio
  • RIGL $7.15
  • RCKT N/A
  • Revenue Growth
  • RIGL 105.62
  • RCKT N/A
  • 52 Week Low
  • RIGL $12.66
  • RCKT $2.19
  • 52 Week High
  • RIGL $43.72
  • RCKT $22.01
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • RCKT 51.17
  • Support Level
  • RIGL $39.00
  • RCKT $2.88
  • Resistance Level
  • RIGL $42.08
  • RCKT $3.74
  • Average True Range (ATR)
  • RIGL 2.32
  • RCKT 0.27
  • MACD
  • RIGL -0.37
  • RCKT 0.02
  • Stochastic Oscillator
  • RIGL 53.26
  • RCKT 35.43

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: